Radiosensitivity in patients affected by ARPC1B deficiency: a new disease trait?
ARPC1B
DNA damage response (DDR)
combined immunodeficiency
immune dysregulation
radiosensitivity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
04
2022
accepted:
30
06
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Actin-related protein 2/3 complex subunit 1B (ARPC1B) deficiency is a recently described inborn error of immunity (IEI) presenting with combined immunodeficiency and characterized by recurrent infections and thrombocytopenia. Manifestations of immune dysregulation, including colitis, vasculitis, and severe dermatitis, associated with eosinophilia, hyper-IgA, and hyper-IgE are also described in ARPC1B-deficient patients. To date, hematopoietic stem cell transplantation seems to be the only curative option for patients. ARPC1B is part of the actin-related protein 2/3 complex (Arp2/3) and cooperates with the Wiskott-Aldrich syndrome protein (WASp) in the regulation of the actin cytoskeleton remodeling and in driving double-strand break clustering for homology-directed repair. In this study, we aimed to investigate radiosensitivity (RS) in ARPC1B-deficient patients to assess whether it can be considered an additional disease trait. First, we performed trio-based next-generation-sequencing studies to obtain the ARPC1B molecular diagnosis in our index case characterized by increased RS, and then we confirmed, using three different methods, an increment of radiosensitivity in all enrolled ARPC1B-deficient patients. In particular, higher levels of chromatid-type aberrations and γH2AX foci, with an increased number of cells arrested in the G2/M-phase of the cell cycle, were found in patients' cells after ionizing radiation exposition and radiomimetic bleomycin treatment. Overall, our data suggest increased radiosensitivity as an additional trait in ARPC1B deficiency and support the necessity to investigate this feature in ARPC1B patients as well as in other IEI with cytoskeleton defects to address specific clinical follow-up and optimize therapeutic interventions.
Identifiants
pubmed: 35967303
doi: 10.3389/fimmu.2022.919237
pmc: PMC9372879
doi:
Substances chimiques
ARPC1B protein, human
0
Actin-Related Protein 2
0
Actin-Related Protein 2-3 Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
919237Informations de copyright
Copyright © 2022 Chiriaco, Ursu, Amodio, Cotugno, Volpi, Berardinelli, Pizzi, Cifaldi, Zoccolillo, Prigione, Di Cesare, Giancotta, Anastasio, Rivalta, Pacillo, Zangari, Fiocchi, Diociaiuti, Bruselles, Pantaleoni, Ciolfi, D’Oria, Palumbo, Gattorno, El Hachem, de Villartay, Finocchi, Palma, Rossi, Tartaglia, Aiuti, Antoccia, Di Matteo and Cancrini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer VB declared a shared affiliation with the author J-PV to the handling editor at the time of review.
Références
Ann Ist Super Sanita. 2009;45(3):265-71
pubmed: 19861731
Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):510-6
pubmed: 19858715
J Cell Biol. 2010 Jul 12;190(1):101-14
pubmed: 20603326
Cell Rep. 2021 Jul 6;36(1):109318
pubmed: 34233185
J Allergy Clin Immunol. 2019 Jan;143(1):325-334.e2
pubmed: 29906526
Int J Mol Sci. 2021 Jul 02;22(13):
pubmed: 34281212
Blood. 2018 Nov 29;132(22):2362-2374
pubmed: 30254128
Nature. 2018 Jul;559(7712):61-66
pubmed: 29925947
Sci Rep. 2019 Jun 4;9(1):8255
pubmed: 31164689
Immunol Rev. 2013 Nov;256(1):282-99
pubmed: 24117828
J Cell Biol. 2019 Feb 4;218(2):422-432
pubmed: 30602538
Front Immunol. 2021 Jan 07;11:604206
pubmed: 33488606
Int J Mol Sci. 2020 Jan 10;21(2):
pubmed: 31936707
JCI Insight. 2021 Dec 8;6(23):
pubmed: 34673575
Transl Cancer Res. 2013;2(3):107-129
pubmed: 24058901
Nat Commun. 2017 Apr 03;8:14816
pubmed: 28368018
Front Immunol. 2021 Feb 19;12:634313
pubmed: 33679784
J Immunol. 2017 Dec 15;199(12):4036-4045
pubmed: 29127144
Cell Cycle. 2012 Nov 15;11(22):4129-34
pubmed: 23032308
Immunol Cell Biol. 2019 Apr;97(4):389-402
pubmed: 30779216
J Allergy Clin Immunol. 2019 Jun;143(6):2296-2299
pubmed: 30771411
Mutat Res. 2020 May - Dec;821:111716
pubmed: 32738522
J Allergy Clin Immunol. 2017 Jul;140(1):273-277.e10
pubmed: 27965109
Oncogene. 2019 Feb;38(6):852-867
pubmed: 30177840
Mutat Res. 2008 Nov 17;657(1):1-2
pubmed: 18793751
Mutat Res. 2012 Aug 1;736(1-2):39-47
pubmed: 21651917
Curr Opin Pediatr. 2013 Aug;25(4):474-9
pubmed: 23817304
J Innate Immun. 2021;13(1):3-25
pubmed: 32846417
Mutagenesis. 2013 Jul;28(4):465-73
pubmed: 23696313
J Allergy Clin Immunol. 2020 Jan;145(1):324-334
pubmed: 31604087
IUBMB Life. 2009 Jun;61(6):591-9
pubmed: 19472175